2014
Self-Management of Buprenorphine/Naloxone Among Online Discussion Board Users
Brown SE, Altice FL. Self-Management of Buprenorphine/Naloxone Among Online Discussion Board Users. Substance Use & Misuse 2014, 49: 1017-1024. PMID: 24779501, PMCID: PMC5592159, DOI: 10.3109/10826084.2014.888449.Peer-Reviewed Original Research
2012
Retention on Buprenorphine Is Associated with High Levels of Maximal Viral Suppression among HIV-Infected Opioid Dependent Released Prisoners
Springer SA, Qiu J, Saber-Tehrani AS, Altice FL. Retention on Buprenorphine Is Associated with High Levels of Maximal Viral Suppression among HIV-Infected Opioid Dependent Released Prisoners. PLOS ONE 2012, 7: e38335. PMID: 22719814, PMCID: PMC3365007, DOI: 10.1371/journal.pone.0038335.Peer-Reviewed Original ResearchConceptsMaximum viral suppressionOpioid dependenceViral suppressionGlobal health qualityMaximal viral suppressionHIV treatment outcomesBuprenorphine/naloxoneCopies/mLChronic relapsing diseaseDSM-IV criteriaAntiretroviral therapyOpioid useProspective trialProspective studyRelapsing diseaseOpioid dependentsTreatment outcomesHIV-1HIVNLXHealth qualityTherapyWeeksSuppressionGroup
2011
Hepatic Safety and Lack of Antiretroviral Interactions With Buprenorphine/Naloxone in HIV-Infected Opioid-Dependent Patients
Vergara-Rodriguez P, Tozzi MJ, Botsko M, Nandi V, Altice F, Egan JE, O'Connor PG, Sullivan LE, Fiellin DA. Hepatic Safety and Lack of Antiretroviral Interactions With Buprenorphine/Naloxone in HIV-Infected Opioid-Dependent Patients. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2011, 56: s62-s67. PMID: 21317596, DOI: 10.1097/qai.0b013e31820a820f.Peer-Reviewed Original ResearchConceptsBuprenorphine/naloxoneOpioid-dependent patientsMedian aspartate aminotransferasePharmacodynamic interactionsAspartate aminotransferaseBup/ALT valuesAlanine aminotransferaseBUP/NXOpioid-dependent HIVProspective cohort studyHepatic safetyHepatitis CCohort studyHepatic toxicityHIVPatientsAtazanavirNaloxonePrior reportsExposure measuresSignificant decreaseAminotransferaseSignificant changesTreatmentHIV Treatment Outcomes Among HIV-Infected, Opioid-Dependent Patients Receiving Buprenorphine/Naloxone Treatment within HIV Clinical Care Settings: Results From a Multisite Study
Altice FL, Bruce RD, Lucas GM, Lum PJ, Korthuis PT, Flanigan TP, Cunningham CO, Sullivan LE, Vergara-Rodriguez P, Fiellin DA, Cajina A, Botsko M, Nandi V, Gourevitch MN, Finkelstein R. HIV Treatment Outcomes Among HIV-Infected, Opioid-Dependent Patients Receiving Buprenorphine/Naloxone Treatment within HIV Clinical Care Settings: Results From a Multisite Study. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2011, 56: s22-s32. PMID: 21317590, PMCID: PMC3263431, DOI: 10.1097/qai.0b013e318209751e.Peer-Reviewed Original ResearchConceptsBUP/NXHIV treatment outcomesCD4 lymphocyte countHIV clinical care settingsAntiretroviral therapyViral suppressionLymphocyte countTreatment outcomesClinical care settingsOpioid dependenceCare settingsLower HIV-1 RNA levelsBuprenorphine/naloxone treatmentHIV-1 RNA levelsInitiation of ARTHIV-1 RNA suppressionComorbid substance use disorderHealth qualityBuprenorphine/naloxoneMultidisciplinary treatment strategyOpioid-dependent patientsGeneral health qualityMental health qualityOpioid-dependent subjectsSubstance use disordersDrug Treatment Outcomes Among HIV-Infected Opioid-Dependent Patients Receiving Buprenorphine/Naloxone
Fiellin DA, Weiss L, Botsko M, Egan JE, Altice FL, Bazerman LB, Chaudhry A, Cunningham CO, Gourevitch MN, Lum PJ, Sullivan LE, Schottenfeld RS, O'Connor PG. Drug Treatment Outcomes Among HIV-Infected Opioid-Dependent Patients Receiving Buprenorphine/Naloxone. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2011, 56: s33-s38. PMID: 21317592, PMCID: PMC3863630, DOI: 10.1097/qai.0b013e3182097537.Peer-Reviewed Original ResearchConceptsBuprenorphine/naloxoneBuprenorphine/naloxone treatmentOpioid-dependent patientsDrug useOpioid useNaloxone treatmentHIV treatment settingsIllicit opioid useOngoing drug useDrug treatment outcomesNaloxone dosesIllicit opioidsOpioid dependenceOffice visitsProspective studyHIV treatmentRetained patientsTreatment outcomesTreatment retentionPatientsTreatment settingsAddiction treatment processNaloxoneTreatment populationHIVImproved Quality of Life for Opioid-Dependent Patients Receiving Buprenorphine Treatment in HIV Clinics
Korthuis PT, Tozzi MJ, Nandi V, Fiellin DA, Weiss L, Egan JE, Botsko M, Acosta A, Gourevitch MN, Hersh D, Hsu J, Boverman J, Altice FL. Improved Quality of Life for Opioid-Dependent Patients Receiving Buprenorphine Treatment in HIV Clinics. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2011, 56: s39-s45. PMID: 21317593, PMCID: PMC3073082, DOI: 10.1097/qai.0b013e318209754c.Peer-Reviewed Original ResearchConceptsSF-12 scoresGeneral US populationOpioid dependenceUS populationPoor health-related qualityShort Form Health SurveyBUP/NXBuprenorphine/naloxoneHIV care settingsOpioid-dependent patientsOpioid-dependent personsForm Health SurveyHealth-related qualityQuality of lifeBup/Mean HRQoLHIV clinicMaintenance therapyBuprenorphine treatmentHIV infectionPhysical HRQoLMental HRQOLHRQoL domainsMixed effects regressionHealth SurveyThe Cost of Integrated HIV Care and Buprenorphine/Naloxone Treatment: Results of a Cross-Site Evaluation
Schackman BR, Leff JA, Botsko M, Fiellin DA, Altice FL, Korthuis PT, Sohler N, Weiss L, Egan JE, Netherland J, Gass J, Finkelstein R. The Cost of Integrated HIV Care and Buprenorphine/Naloxone Treatment: Results of a Cross-Site Evaluation. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2011, 56: s76-s82. PMID: 21317599, PMCID: PMC3270565, DOI: 10.1097/qai.0b013e31820a9a66.Peer-Reviewed Original ResearchConceptsBuprenorphine/naloxone treatmentIntegrated care patientsBuprenorphine/naloxoneNaloxone treatmentCare patientsClinic costsIntegrated careCross-site evaluationHIV clinical sitesIntegrated HIV careUrine toxicology analysisMedian monthly costPotential cost offsetsToxicology analysisHIV careIntegrated HIVSimilar patientsPhysician encountersPatient costsClinic settingMedian numberProvider encountersPatient timePatientsClinical sitesImproving Adherence to HIV Quality of Care Indicators in Persons With Opioid Dependence: The Role of Buprenorphine
Korthuis PT, Fiellin DA, Fu R, Lum PJ, Altice FL, Sohler N, Tozzi MJ, Asch SM, Botsko M, Fishl M, Flanigan TP, Boverman J, McCarty D. Improving Adherence to HIV Quality of Care Indicators in Persons With Opioid Dependence: The Role of Buprenorphine. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2011, 56: s83-s90. PMID: 21317600, PMCID: PMC3066190, DOI: 10.1097/qai.0b013e31820bc9a5.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveBuprenorphineBuprenorphine, Naloxone Drug CombinationCohort StudiesFemaleGuideline AdherenceHIV InfectionsHumansMaleMiddle AgedMultivariate AnalysisNaloxoneNarcotic AntagonistsOpiate Substitution TreatmentOpioid-Related DisordersPractice Guidelines as TopicQuality of Health CareConceptsBUP/NXHIV careOpioid dependenceHIV qualitySummary quality scoresCare indicatorsBuprenorphine/naloxone maintenance therapyHigh-quality HIV careOpioid-dependent HIVRole of buprenorphineObservational cohort studyOpioid-dependent patientsQuality scoresNondependent patientsHIV clinicMaintenance therapyCohort studyBuprenorphine treatmentClinical outcomesMultivariable analysisMedical recordsPatientsCareMonthsHIVIntegration of Buprenorphine/Naloxone Treatment into HIV Clinical Care: Lessons From the BHIVES Collaborative
Weiss L, Netherland J, Egan JE, Flanigan TP, Fiellin DA, Finkelstein R, Altice FL. Integration of Buprenorphine/Naloxone Treatment into HIV Clinical Care: Lessons From the BHIVES Collaborative. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2011, 56: s68-s75. PMID: 21317597, DOI: 10.1097/qai.0b013e31820a8226.Peer-Reviewed Original ResearchMeSH KeywordsAmbulatory CareAnti-HIV AgentsBuprenorphineBuprenorphine, Naloxone Drug CombinationDelivery of Health Care, IntegratedHealth ResourcesHealth Services Needs and DemandHIV InfectionsHumansNaloxoneNarcotic AntagonistsOpiate Substitution TreatmentOpioid-Related DisordersPrimary Health CareSubstance Abuse Treatment CentersUnited StatesConceptsBUP/NXHIV clinical careBup/HIV evaluationClinical careBuprenorphine/naloxone treatmentGeneral internal medicine physiciansHospital-based clinicsInternal medicine physiciansSite principal investigatorsExperiences of physiciansMental health issuesPrincipal investigatorHIV providersMultisubstance useNX treatmentHIV careIntegrated HIVNaloxone treatmentUrine toxicologyMultiple prescribersHIV treatmentMedicine physiciansTreatment servicesProvider experience
2010
Pharmacokinetic Interactions Between Buprenorphine/Naloxone and Once-Daily Lopinavir/Ritonavir
Bruce RD, Altice FL, Moody DE, Morse GD, Andrews L, Lin SN, Fang WB, Ma Q, Friedland GH. Pharmacokinetic Interactions Between Buprenorphine/Naloxone and Once-Daily Lopinavir/Ritonavir. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2010, 54: 511-514. PMID: 20672450, PMCID: PMC4841260, DOI: 10.1097/qai.0b013e3181d3cad3.Peer-Reviewed Original ResearchConceptsLPV/rBuprenorphine/naloxoneHIV-seronegative subjectsLopinavir/ritonavirOpioid withdrawalPharmacokinetic interactionsDaily lopinavir/ritonavirDaily LPV/rSteady-state pharmacokinetic evaluationBuprenorphine pharmacokineticsR administrationDosage modificationNaloxone concentrationsHistorical controlsPharmacodynamic responseAUC0-24hBaseline valuesPharmacokinetic evaluationNaloxonePharmacokinetic studySignificant differencesRitonavirNLXCmaxClearanceImproved HIV and Substance Abuse Treatment Outcomes for Released HIV-Infected Prisoners: The Impact of Buprenorphine Treatment
Springer SA, Chen S, Altice FL. Improved HIV and Substance Abuse Treatment Outcomes for Released HIV-Infected Prisoners: The Impact of Buprenorphine Treatment. Journal Of Urban Health 2010, 87: 592-602. PMID: 20177974, PMCID: PMC2900572, DOI: 10.1007/s11524-010-9438-4.Peer-Reviewed Original ResearchConceptsOpioid agonist therapySubstance abuse treatment outcomesTreatment outcomesNon-detectable viral loadOpioid treatment outcomesBuprenorphine/naloxoneDSM-IV criteriaAgonist therapyAntiretroviral therapyCD4 countOpioid cravingAdverse eventsBuprenorphine treatmentOpioid dependenceViral loadUrine testingHIVTherapyVulnerable populationsWeeksOutcomesNLXTrialsInductionLikert scale
2009
Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone
Bruce RD, Altice FL, Moody DE, Lin SN, Fang WB, Sabo JP, Wruck JM, Piliero PJ, Conner C, Andrews L, Friedland GH. Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone. Drug And Alcohol Dependence 2009, 105: 234-239. PMID: 19726139, PMCID: PMC2779257, DOI: 10.1016/j.drugalcdep.2009.07.007.Peer-Reviewed Original ResearchConceptsTPV/rBuprenorphine/naloxonePharmacokinetic interactionsBuprenorphine/naloxone therapySteady-state pharmacokinetic evaluationOpioid replacement therapyHIV-negative subjectsHIV-seronegative subjectsOpioid withdrawal symptomsHistorical control subjectsTipranavir/ritonavirConcentration-time profilesRTV levelsAntiretroviral medicationsDosage modificationNaloxone therapyTreatment medicationsOpioid dependenceReplacement therapyWithdrawal symptomsControl subjectsPharmacokinetic effectsHIV therapyPharmacokinetic evaluationNLXLack of Reduction in Buprenorphine Injection After Introduction of Co-Formulated Buprenorphine/Naloxone to the Malaysian Market
Bruce RD, Govindasamy S, Sylla L, Kamarulzaman A, Altice FL. Lack of Reduction in Buprenorphine Injection After Introduction of Co-Formulated Buprenorphine/Naloxone to the Malaysian Market. The American Journal Of Drug And Alcohol Abuse 2009, 35: 68-72. PMID: 19212931, PMCID: PMC2791788, DOI: 10.1080/00952990802585406.Peer-Reviewed Original ResearchConceptsBuprenorphine/naloxoneOpioid withdrawal symptomsSyringe sharingWithdrawal symptomsSnowball recruitment techniquesLogistic regression analysisDiversion of buprenorphineLack of reductionEvidence-based approachPrimary outcomeBuprenorphine injectionOnly symptomBenzodiazepine useBenzodiazepine injectionStomach painBuprenorphineInjection doseRisk behaviorsSymptomsNaloxoneInjectionRegression analysisNLXDaily amountDose
2007
Case Series on the Safe Use of Buprenorphine/Naloxone in Individuals with Acute Hepatitis C Infection and Abnormal Hepatic Liver Transaminases
Bruce RD, Altice FL. Case Series on the Safe Use of Buprenorphine/Naloxone in Individuals with Acute Hepatitis C Infection and Abnormal Hepatic Liver Transaminases. The American Journal Of Drug And Alcohol Abuse 2007, 33: 869-874. PMID: 17994482, DOI: 10.1080/00952990701653875.Peer-Reviewed Original ResearchConceptsHepatitis C virusAcute hepatitis C infectionHepatitis C infectionBuprenorphine treatmentC infectionChronic viral illnessesSafety of buprenorphineAcute HCV infectionBuprenorphine/naloxoneOpiate substitution therapyOpioid-dependent patientsOpiate substitution treatmentLaboratory evaluationChronic hepatitisElevated transaminasesHCV infectionLiver transaminasesViral illnessCase seriesSubstitution therapyC virusSubstitution treatmentBuprenorphinePatientsTransaminase